Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials - Bogman, Katrijn; Brumm, Jochen; Hofmann, Carsten; Giraudon, Mylène; Niggli, Markus; Sturm-Pellanda, Carolina; Sauter, Annette; Sturm, Stefan; Mangold, Bernhard; Schmitt, Christophe (Clinical pharmacokinetics, 2019)
Keywords: Administration, Oral; Adult; Agonists; Angiotensin-Converting Enzyme Inhibitors - administration & dosage; Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - pharmacokinetics; Anticoagulants - administration & dosage; Anticoagulants - pharmacokinetics; Birth control; Cardiotonic Agents - administration & dosage; Cardiotonic Agents - pharmacokinetics; Case-Control Studies; Clinical medicine; Confidence intervals; Contraceptives, Oral - administration & dosage; Contraceptives, Oral - pharmacokinetics; Cytochrome; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Digoxin - administration & dosage; Digoxin - pharmacokinetics; Drug dosages; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1 - agonists; Healthy Volunteers; Humans; Injections, Subcutaneous; Internal Medicine; Lisinopril - administration & dosage; Lisinopril - pharmacokinetics; Male; Medicine; Medicine & Public Health; Middle Aged; Original Research Article; Peptides; Peptides - administration & dosage; Peptides - adverse effects; Peptides - pharmacology; Pharmaceutical Preparations - blood; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Simvastatin - administration & dosage; Simvastatin - pharmacokinetics; Vomiting; Warfarin - administration & dosage; Warfarin - pharmacokinetics